Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours Β· Estimated delivery Sep 26 - Oct 1
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
Simulated chronic jet lag affects the structural and functional complexity of hippocampal neurons in mice
In contrast, levels of high-sensitivity C-reactive protein (a biomarker of inflammation) and sCD163 (a marker of macrophage activation) were correlated with better scores
Diabetes Obes Metab (2018) 20(1):20005
US$ 28.90
US$ 27.80
US$ 25.99
US$ 25.73
US$ 20.66
US$ 25.93
